Benign prostatic hyperplasia is a noncancerous medical condition in which the prostate size increases. There are several options available for treating this such as changes in the client’s lifestyle, self-catheterization, surgery and a number of medications. There are choices available for treatment using drugs.
Market for BPH drugs
The global market for benign prostatic hyperplasia (BPH) drugs is expected to increase at a higher compound annual growth rate (CAGR) during the forecast period of 2017-2022. The development in the medical field which has introduced options for diagnosis of the medical condition at an early stage which has been the market driving factor for this. The growth in the patient pool due to diagnostic tests giving better results than the conventional methods has led to the expansion of the market industry for BPH drugs.
More information regarding BPH drugs
The choice of treatment for benign prostatic hyperplasia is decided depending on several factors which include client’s age, overall health, prostate size and the extent of bother or discomfort experienced by the client. In case the symptoms of the condition are within the limits of tolerance, one might prefer postponing the treatment and keep his symptoms in track. Regarding the treatment, use of medications is the most preferred option amongst all others. These are applicable in clients exhibiting mild to moderate symptoms for the enlargement of prostate. The drugs provide relief from bothersome urination problems ranging from moderate to severe which are the results of BPH. In case the client stops taking these drugs, the symptoms reappear generally. These drugs carry minor side effects which stop when the client is no more relying on these. There are options available. Alpha blockers form a class of drugs used in treating BPH. These work by relaxing the muscles present on the neck of the bladder and the prostatic muscle fibers, thus easing the process of urination. Drugs belonging to this class such as doxazosin (Cardura), silodosin (Rapaflo), alfuzosin (Uroxatral) and tamsulosin (Flomax) give faster results in clients having smaller prostates. Another class is that of 5-alpha reductase inhibitors. These work by shrinking the prostate by causing prevention of hormonal changes which lead to prostate growth. Examples are dutasteride (Avodart) and finasteride (Proscar). Combination drug therapy is another option which involves the administration of alpha blocker and 5-alpha reductase inhibitor combination. Tadalafil (Cialis) is another treatment drug. This medication has been found to be effective in treating BPH but is not very common is use.
The increasing incidents of BPH have led to the demand for treatment options. The related drugs offer a good option which minimal number of side effects, hence leading to the market growth.